New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

Patients with generalized pustular psoriasis continued to experience frequent flares that were often uncontrolled by ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Patients with atopic dermatitis, psoriasis, or vitiligo who use immunosuppressants or were vaccinated against COVID-19 are not at an increased risk of developing COVID-19. Investigators examined the ...

Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms and soles. These plaques can crack open and ...